心脏移植围手术期受甲状腺激素状态影响
这项前瞻性单中心队列研究纳入2013至2020年在匈牙利Semmelweis大学心脏与血管中心接受心脏移植的283例患者,术前术后检测血清fT3、fT4和TSH,并检测心肌Dio2、Dio3 mRNA。心脏移植术后TSH、fT3、fT4均低于术前;供体接受左甲状腺素与受体术后接受左甲状腺素替代均与更好的30天生存相关,受体替代还与1年、2年生存相关。作者认为甲状腺激素状态在心脏移植患者中起重要作用,围手术期监测可能有助于改善治疗结局,但需随机对照临床试验独立验证。
要点
- 心脏移植术后血清TSH、fT3、fT4水平均低于术前。
- 供体接受左甲状腺素与术后30天生存更好相关。
- 受体术后左甲状腺素替代与30天、1年、2年生存更好相关。
核心结论
- 甲状腺激素状态在心脏移植患者中起重要作用,围手术期监测甲状腺激素状态可能有助于改善治疗结局。
- 作者的发现需在随机对照临床试验中独立验证。
研究设计与样本
- 前瞻性单中心队列研究,纳入2013至2020年在匈牙利Semmelweis大学心脏与血管中心接受心脏移植的283例患者。
- 术前和术后检测血清游离三碘甲状腺原氨酸(fT3)、游离甲状腺素(fT4)和促甲状腺激素(TSH)。
- 采用TaqMan qPCR检测病心活检组织中2型脱碘酶和3型脱碘酶mRNA(分别为Dio2和Dio3)水平。
- 在术后接受体外膜氧合(ECMO)的亚组患者中检测Hcn2和Myh7 mRNA水平以评估心脏局部甲状腺激素作用。
- 组间比较采用非参数检验,结局分析采用Cox回归和logistic回归,血清甲状腺激素参数与心脏基因表达的关系采用线性回归评估。
主要发现
- 心脏移植术后血清TSH(p = 0.009)、fT3(p < 0.001)和fT4(p < 0.001)水平均低于术前。
- 供体接受左甲状腺素与术后30天生存更好相关(p = 0.049)。
- 受体心脏移植后接受左甲状腺素替代与术后30天(p = 0.018)、1年(p = 0.002)和2年(p = 0.001)生存更好相关。
- 与不需要任何类型机械循环支持(MCS)的患者相比,术前接受ECMO(p = 0.026)、左心室辅助装置(LVAD)(p = 0.008)和双心室辅助装置(BiVAD)(p = 0.013)以及术后接受ECMO(p = 0.042)的患者Dio3 mRNA水平显著升高。
- 术后接受ECMO的患者与无MCS患者之间Hcn2和Myh7标记基因表达无显著差异,且这些基因表达与血清激素水平无相关性(分别为p = 0.519和p = 0.056)。
临床怎么用
- 作者认为围手术期监测甲状腺激素状态可能有助于改善心脏移植患者的治疗结局。
- 作者指出其发现需在随机对照临床试验中独立验证。
局限性
- 作者的发现需在随机对照临床试验中独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Orthotopic heart transplantation (HTx) is a long-term surgical therapeutic approach for patients with end-stage heart failure. The objective of the present study was to uncover associations between altered thyroid hormone (TH) status and adverse outcomes after HTx. Methods: In this prospective, single-center cohort study, 283 patients underwent HTx between 2013 and 2020 at the Heart and Vascular Center of Semmelweis University in Hungary. We measured serum free triiodothyronine (fT3), free thyroxine (fT4), and thyrotropin (TSH) pre- and postoperatively. TaqMan qPCR was used to measure type 2 deiodinase and type 3 deiodinase mRNA (Dio2 and Dio3, respectively) levels from the diseased heart bioptates. To assess the local TH action of the heart, mRNA levels of Hcn2 and Myh7 were measured in a subgroup of patients receiving extracorporeal membrane oxygenation (ECMO) postoperatively. Groups were compared using nonparametric tests. Cox regression analysis and logistic regression test were used to investigate the outcomes. The connection between serum TH parameters and cardiac gene expressions was assessed using linear regression. Results: Serum TSH (p = 0.009), fT3 (p < 0.001), and fT4 (p < 0.001) levels were lower after HTx than preoperatively. Levothyroxine (LT4) administered to donors was associated with better survival after 30 days (p = 0.049). LT4 replacement given to recipients after HTx was associated with better survival after 30 days (p = 0.018), 1 year (p = 0.002), and 2 years (p = 0.001). Dio3 mRNA level was significantly increased in patients who were treated with ECMO (p = 0.026), left ventricular assist device (LVAD) (p = 0.008), and biventricular assist device (BiVAD) (p = 0.013) preoperatively, and ECMO (p = 0.042) postoperatively, compared with those who did not require any type of mechanical circulatory support (MCS). We found no significant difference in the expression of the Hcn2 and Myh7 marker genes between patients on postoperative ECMO and those without MCS, and neither did they correlate with serum hormone levels (p = 0.519 and p = 0.056, respectively). Conclusions: We conclude that TH status plays an important role in HTx patients, and monitoring of TH status in the perioperative period may contribute to improved treatment outcomes. Our findings require independent confirmation in a randomized controlled clinical trial.
引用
- Szécsi B, Sinkó R, Vereb A, et al. The Perioperative Period of Heart Transplantation Is Affected by Thyroid Hormone Status. Thyroid. 2024. PMID: 38613807. doi:10.1089/thy.2023.0628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。